Sanofi Revenue 2006-2018 | SNY
Sanofi annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Sanofi revenue for the quarter ending June 30, 2018 was $0.000B, a 100% decline year-over-year.
- Sanofi revenue for the twelve months ending June 30, 2018 was $31.600B, a 20.17% decline year-over-year.
- Sanofi annual revenue for 2018 was $42.135B, a 2.96% increase from 2017.
- Sanofi annual revenue for 2017 was $40.921B, a 6.54% increase from 2016.
- Sanofi annual revenue for 2016 was $38.408B, a 0.78% decline from 2015.
Sanofi Annual Revenue
(Millions of US $) |
| 2018 |
$42,135 |
| 2017 |
$40,921 |
| 2016 |
$38,408 |
| 2015 |
$38,710 |
| 2014 |
$45,341 |
| 2013 |
$44,240 |
| 2012 |
$46,244 |
| 2011 |
$48,829 |
| 2010 |
$42,539 |
| 2009 |
$42,883 |
| 2008 |
$42,398 |
| 2007 |
$40,034 |
| 2006 |
$37,044 |
| 2005 |
$35,510 |
Sanofi Quarterly Revenue
(Millions of US $) |
| Q2 2018 |
$0 |
| Q1 2018 |
$9,988 |
| Q4 2017 |
$10,572 |
| Q3 2017 |
$11,040 |
| Q2 2017 |
$9,828 |
| Q1 2017 |
$9,482 |
| Q4 2016 |
$9,904 |
| Q3 2016 |
$10,373 |
| Q2 2016 |
$9,385 |
| Q1 2016 |
$8,746 |
| Q3 2015 |
$10,770 |
| Q2 2015 |
$10,466 |
| Q2 2014 |
$11,175 |
| Q2 2013 |
$10,560 |
| Q2 2012 |
$11,716 |
| Q1 2012 |
$11,247 |
| Q4 2011 |
$11,701 |
| Q3 2011 |
$12,087 |
| Q2 2011 |
$12,061 |
| Q1 2011 |
$11,423 |
| Q4 2010 |
$10,075 |
| Q3 2010 |
$10,788 |
| Q2 2010 |
$10,648 |
| Q1 2010 |
$9,748 |
| Q4 2009 |
$10,098 |
| Q3 2009 |
$10,922 |
| Q2 2009 |
$10,582 |
| Q1 2009 |
$9,190 |
| Q4 2008 |
$9,834 |
| Q3 2008 |
$10,127 |
| Q2 2008 |
$10,407 |
| Q1 2008 |
$10,519 |
| Q4 2007 |
$10,366 |
| Q3 2007 |
$10,133 |
| Q2 2007 |
$9,356 |
| Q1 2007 |
$9,737 |
| Q4 2006 |
$9,489 |
| Q3 2006 |
$8,848 |
| Q2 2006 |
$8,897 |
| Q1 2006 |
$8,463 |
| Q4 2005 |
$8,342 |
| Q3 2005 |
$8,784 |
| Q2 2005 |
$8,430 |
| Q1 2005 |
$8,419 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$111.008B |
$40.701B |
|
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
|
